1. Lazarou J, Pomeranz B, Corey P: Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 279:1200-1205, 1998
2. Bigby M: Rates of cutaneous reactions to drugs. Arch Dermatol 137:765-770, 2001
3. Segal A et al: Cutaneous reactions to drugs in children. Pediatrics 120:e1082-e1096, 2007
4. Batchelor J et al: Hydralazine-induced systemic lupus erythematosus: Influence of HLA-DR and sex on susceptibility. Lancet 1:1107-1109, 1980
5. Hung S et al: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 16:297-306, 2006
6. Dainichi T et al: Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by
allopurinol in patients with a common HLA allele: What causes the diversity.
Dermatology 215:86-88, 2007
7. Tozzi V: Pharmacogenetics of antiretrovirals. Antiviral Res 85:190-200, 2010
8. Uetrecht J: Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions? Curr Drug Metab 1:133-141, 2000
9. Shear N, Spielberg S: Anticonvulsant hypersensitivity syndrome, in vitro assessment of risk. J Clin Invest 82:1826-1832, 1988
10. Seishima M et al: Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol 155:344-349, 2006
11. Walsh SA, Creamer D: Drug reaction with eosinophilia and systemic symptoms (DRESS): A clinical update and review of current thinking. Clin Exp Derm 36:6-11, 2011
12. Sullivan J, Shear N: What are some of the lessons learnt from in vitro studies of severe unpredictable drug reactions? Br J Dermatol 142:205, 2000
13. Bastuji-Garin S et al: SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115:149, 2000
14. Khan D, Solensky R: Drug allergy. J Allergy Clin Immunol 125:S126-S137, 2010
15. Valeyrie-Allanore L, Sassolas B, Roujeau J: Drug-induced skin, nail and hair disorders. Drug Safety 30:1011-1030, 2007
16. Schnyder B, Pichler W: Mechanisms of drug-induced allergy. Mayo Clin Proc 84:268-272, 2009
17. Kerns D, Shira J, Go S:
Ampicillin rash in children.
Am J Dis Child 125:187-190, 1973
18. Gupta A et al: Drug-induced hypothyroidism: The thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 51:56-67, 1992
19. Castrejon J et al: Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J Allergy Clin Immunol 125:411-418, 2010
20. Knowles S, Shapiro L, Shear N: Should
celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of “sulfa” allergy.
Drug Safety 24:239-247, 2001
21. Chiou C et al: Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: A study of 30 cases in Taiwan. J Eur Acad Dermatol Venereol 22:1044-1049, 2008
22. Tassaneeyakul W et al: Strong assocation between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 19:704-709, 2009
23. Kearns G et al: Serum sickness-like reactions to
cefaclor: Role of hepatic metabolism and individual susceptibility.
J Pediatr 125:805-811, 1994
24. Todd D, Helfgott S: Serum sickness following treatment with
rituximab.
J Rheumatol 34:430-433, 2007
25. Gamarra R et al: Serum sickness-like reactions in patients receiving intravenous
infliximab.
J Emerg Med 30:41-44, 2006
26. Remmer H, Falk W: Successful treatment of lithium-induced acne. J Clin Psychiatry 47:48, 1986
27. Cowen E: Epidermal growth factor receptor inhibitors: A new era of drug reactions in a new era of cancer therapy. J Am Acad Dermatol 56:514-517, 2007
28. Su X et al: Risk of hig-grade skin rash in cancer patients treated with
cetuximab: An antibody against epidermal growth factor receptor: Systemic review and meta-analysis.
Oncology 77:124-133, 2009
29. Guevara-Gutierrez E et al: Acute generalized exanthematous pustulosis: Report of 12 cases and literature review. Int J Dermatol 48:253-258, 2009
30. Britschgi M, Pichler W: Acute generalized exanthematous pustulosis, a clue to neturophil-mediated inflammatory processes orchestrated by T cells. Curr Opin Allergy Clin Immunol 2:325-331, 2002
31. Lang B, Finlayson L: Naproxen-induced pseudoporphyria in patients with juvenile rheumatoid arthritis. J Pediatr 124:639-642, 1994
32. Tolland J, McKeown P, Corbett J: Voriconazole-induced pseudoporphyria. Photodermatol Photoimmunol Photomed 23:29-31, 2007
33. LaDuca J, Bouman P, Gaspari A: Nonsteroidal antiinflammatory drug-induced pseudoporphyria: A case series. J Cutan Med Surg 6:320-326, 2002
34. Primka E et al: Amiodarone-induced linear IgA disease. J Am Acad Dermatol 31:809-811, 1994
35. Panasiti V et al: Amoxicillin-clavulanic acid-induced linear immunoglobulin A bullous dermatosis: Case report and review of the literature. Int J Dermatol 48:1006-1110, 2009
36. Ruocco V, Sacerdoti G: Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol 30:307-312, 1991
37. Lee J, Downham T: Furosemide-induced bullous pemphigoid: Case report and review of literature. J Drugs Dermatol 5:562-564, 2006
38. Paquet P, Pierard G: New insights in toxic epidermal necrolysis (Lyell's syndrome): Clinical considerationsk, pathobiology and targeted treatments revistied. Drug Safety 33:189-212, 2010
39. Mockenhaupt M: Severe drug-induced skin reactions: Clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges 7:142-160, 2009
40. Tripathi J et al: Corticosteroid therapy in an adidtional 13 cases of Stevens-Johnson syndrome: A total series of 67 cases. Allergy Asthma Proc 21:101-105, 2000
41. Murphy J, Purdue G, Hunt J: Toxic epidermal necrolysis. Burn Care Rehabil 18:417-420, 1997
42. Schneck J et al: Effects of treatments of the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 58:33-40, 2008
43. Arevalo J et al: Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 48:473-478, 2000
44. Barbaud A et al: Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 45:321-328, 2001
45. Ozkaya E: Fixed drug eruption: State of the art. J Drugs Dermatol 6:181-188, 2008
46. Nazarian R et al: Warfarin-induced skin necrosis. J Am Acad Dermatol 61:325-332, 2009
47. Bircher A et al: Hypersensitivity reactions to anticoagulant drugs: Diagnosis and management options. Allergy 61:1432-1440, 2006
48. Asarch A et al: Lichen planus-like eruptions: An emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 61:104-111, 2009
49. Kerbleski J, Gottlieb A: Dermatological complications and safety of anti-TNF treatments. Gut 58:1033-1039, 2009
50. Halevy S, Shai A: Lichenoid drug eruptions. J Am Acad Dermatol 29:249-255, 1993
51. Albrecht J, Fine L, Piette W: Drug-associated lymphoma and pseudolymphoma: Recognition and management. Dermatol Clin 25:233-244, 2007
52. Scheinfeld N: Impact of
phenytoin therapy on the skin and skin disease.
Expert Opin Drug Saf 3:655-665, 2004
53. Justiniano H, Berlingeri-Ramos A, Sanchez J: Pattery analysis of drug-induced skin diseases. Am J Dermatopathol 30:352-369, 2008
54. Antonov D et al: Drug-induced lupus erythematosus. Clin Dermatol 22:157-166, 2004
55. Dunphy J et al: Antineutrophil cytoplasmic antibodies and HLA class II alleles in minocycline-induced lupus-like syndrome. Br J Dermatol 142:461-467, 2000
56. Rubin R: Drug-induced lupus. Toxicology 209:135-147, 2005
57. Sarzi-Puttini P et al: Drug-induced lupus erythematosus. Autoimmunity 38:507-518, 2005
58. Marzano A, Vezzoli P, Crosti C: Drug-induced lupus: An update on its dermatologic aspects. Lupus 18:935-940, 2009
59. Auquier-Dunant A et al: Correlations between clinical patterns and causes of erythema multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 138:1019-1024, 2002
60. Neuman M, Malkiewicz I, Shear N: A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes. Clin Biochem 33:517-524, 2000
61. Barbaud A: Drug patch testing in systemic cutaneous drug allergy. Toxicology 209:209-216, 2005
62. Shear N et al: A review of drug patch testing and implications for HIV clinicians. AIDS 22:1-9, 2008
63. Drake L et al: Guidelines of care for cutaneous adverse drug reactions. J Am Acad Dermatol 35:458-461, 1996
64. Brennan P et al: Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 124:1259-1266, 2009